Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead

One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhala...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2015-05, Vol.85, p.65-82
Main Authors: Velkov, Tony, Abdul Rahim, Nusaibah, Zhou, Qi (Tony), Chan, Hak-Kim, Li, Jian
Format: Article
Language:English
Subjects:
Administration, Inhalation
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antifungal Agents - administration & dosage
Antifungal Agents - chemistry
Antifungal Agents - therapeutic use
Antifungals
Antiviral Agents - administration & dosage
Antiviral Agents - chemistry
Antiviral Agents - therapeutic use
Antivirals
Clinical Trials as Topic
Drug Delivery Systems - instrumentation
Drug Delivery Systems - methods
Humans
Inhalation
Molecular Structure
Pharmacokinetics/pharmacodynamics
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Respiratory Tract Infections - virology
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety. [Display omitted]
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2014.11.004